Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status

Onkologie(Czech Republic)

Volumn 36, Issue 11, 2013, Pages 670-673

  Gastaud, Lauris ^a   Saâda Bouzid, Esma ^a   Le Morvan, Valérie ^b   Pourquier, Philippe ^b   Ianessi, Antoine ^a   Thariat, Juliette ^a   Italiano, Antoine ^b   Thyss, Antoine ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

DNA excision repair protein group ERCC5; Osteosarcoma; Trabectedin; XPG

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; TRABECTEDIN;

ADOLESCENT; ADRENAL METASTASIS; ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG WITHDRAWAL; ERCC1 GENE; ERCC5 GENE; FEMALE; GENE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMERUS; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MALE; MEDICAL HISTORY; METASTASIS; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PERITONEUM METASTASIS; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADOLESCENT; BONE NEOPLASMS; DIOXOLES; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC MARKERS; HUMANS; MALE; NUCLEAR PROTEINS; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAHYDROISOQUINOLINES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84888316444     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000355664     Document Type: Article

References (18)

1. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C: Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-1230.
2. Hogendoorn PC, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D: Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v204-213.
3. Bacci G, Briccoli A, Mercuri M, Ferrari S, Bertoni F, Gasbarrini A, Fabbri N, Cesari M, Forni C, Campanacci M: Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998;10:69-76.
4. Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, Hogendoorn P, Jimeno J, Evrard V, van Glabbeke M, Judson I: A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2004;40:1327-1331.
5. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-840.
6. Ruiz-Casado A, Lopez-Martin J, Nieto A, Blay J-Y, Delaloge S, Van Oosterom A, Millan S, Martin C, Guzman C, Jimeno J: Ecteinascidin in heavily pretreated advanced sarcoma patients as a compassionate basis. Proc Am Soc Clin Oncol 2002;21:abstr 1631.
7. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase ii study of two different schedules. J Clin Oncol 2009; 27:4188-4196.
8. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray- Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005; 23:576-584.
9. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490.
10. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
11. Italiano A, Laurand A, Laroche A, Casali P, Sanfilippo R, Le Cesne A, Judson I, Blay JY, Ray- Coquard I, Bui B, Coindre JM, Nieto A, Tercero JC, Jimeno J, Robert J, Pourquier P: ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011;117:3445-3456.
12. Huygh G, Clement PM, Dumez H, Schoffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, Van Oosterom AT: Ecteinascidin- 743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006;2006:56282.
13. Dileo P, Bacci G, Aglietta M, Ferrari S, Gignani G, Sessa C, Jimeno J, Marsoni S, Casali P: Final results of a phase II trial of 3 hr infusion trabectidin in patients with recurrent sarcoma. 31st Esmo Congress, Istanbul, Turkey, 2006, abstr. 524 P.
14. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-966.
15. Biason P, Hattinger CM, Innocenti F, Talamini R, Alberghini M, Scotlandi K, Zanusso C, Serra M, Toffoli G: Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy; Pharmacogenomics J 2012;12:476-483.
16. Caronia D, Patino-Garcia A, Milne RL, Zalacain- Diez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga- Ariznabarreta L, Benitez J, Gonzalez- Neira A: Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009;9:347-353.
17. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S: Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-8162.
18. Mirabello L, Yu K, Berndt SI, Burdett L, Wang Z, Chowdhury S, Teshome K, Uzoka A, Hutchinson A, Grotmol T, Douglass C, Hayes RB, Hoover RN, Savage SA: A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma; BMC Cancer 2011;11:209.